Literature DB >> 17629419

K-ras mutation detection in colorectal cancer using the Pyrosequencing technique.

Angela Poehlmann1, Doerthe Kuester, Frank Meyer, Hans Lippert, Albert Roessner, Regine Schneider-Stock.   

Abstract

The identification of gene mutations is a critical goal for the assessment of diagnosis and prognosis in cancer disease, particularly by direct sequencing. Pyrosequencing is a straightforward, non-electrophoretic DNA sequencing method using the luciferase-luciferin light release as a signal for nucleotide incorporation into a PCR template DNA. In this study, we aimed to investigate mutations in the K-ras gene using Pyrosequencing technology, because its reliable chemistry and robust detection mechanism allow for rapid, real-time detection of sequencing events. For the simultaneous detection of the predominant K-ras codons 12 and 13 mutations, we established a sequencing protocol based on the design of a single PCR primer pair and a single sequencing primer. The assay has been validated with DNA from 65 colorectal carcinomas. Furthermore, analysis of the rare K-ras codon 61 mutation was included. In 29% (19/65) of the patients, the K-ras gene was found to be mutated, whereas codons 12 and 13 were most frequently affected (18/65, 27.7%). Mutations with the highest frequency were G-->A transitions (12/19, 63%), followed by G-->T transversions (5/19, 26%). Overall survival was significantly shorter in patients with a tumor containing K-ras codon 12 mutations than in those without K-ras codon 12 mutations (p=0.024). In conclusion, we found Pyrosequencing to be a suitable technology for fast detection of hot-spot mutations in the K-ras oncogene. We demonstrated an important relationship between K-ras codon 12 mutations and overall survival in colorectal cancer patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17629419     DOI: 10.1016/j.prp.2007.06.001

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  29 in total

Review 1.  KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.

Authors:  J H J M van Krieken; A Jung; T Kirchner; F Carneiro; R Seruca; F T Bosman; P Quirke; J F Fléjou; T Plato Hansen; G de Hertogh; P Jares; C Langner; G Hoefler; M Ligtenberg; D Tiniakos; S Tejpar; G Bevilacqua; A Ensari
Journal:  Virchows Arch       Date:  2008-09-18       Impact factor: 4.064

2.  KRAS assay selection: sensitivity and accuracy in clinical application.

Authors:  Marta Herreros-Villanueva; Gaurav Aggarwal
Journal:  Mol Biol Rep       Date:  2011-06-09       Impact factor: 2.316

Review 3.  A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.

Authors:  Vanessa Deschoolmeester; Marc Baay; Pol Specenier; Filip Lardon; Jan B Vermorken
Journal:  Oncologist       Date:  2010-06-28

4.  SNP identification, verification, and utility for population genetics in a non-model genus.

Authors:  Larissa M Williams; Xin Ma; Adam R Boyko; Carlos D Bustamante; Marjorie F Oleksiak
Journal:  BMC Genet       Date:  2010-04-30       Impact factor: 2.797

5.  Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study.

Authors:  Adam Naguib; Panagiota N Mitrou; Laura J Gay; James C Cooke; Robert N Luben; Richard Y Ball; Alison McTaggart; Mark J Arends; Sheila A Rodwell
Journal:  BMC Cancer       Date:  2010-03-16       Impact factor: 4.430

6.  KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis.

Authors:  V Deschoolmeester; C Boeckx; M Baay; J Weyler; W Wuyts; E Van Marck; M Peeters; F Lardon; J B Vermorken
Journal:  Br J Cancer       Date:  2010-10-19       Impact factor: 7.640

7.  Mutations in the WTX-gene are found in some high-grade microsatellite instable (MSI-H) colorectal cancers.

Authors:  Silvio K Scheel; Marc Porzner; Sabine Pfeiffer; Steffen Ormanns; Thomas Kirchner; Andreas Jung
Journal:  BMC Cancer       Date:  2010-08-09       Impact factor: 4.430

8.  Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing.

Authors:  Allison M Cushman-Vokoun; Daniel G Stover; Zhiguo Zhao; Elizabeth A Koehler; Jordan D Berlin; Cindy L Vnencak-Jones
Journal:  Clin Colorectal Cancer       Date:  2013-06-14       Impact factor: 4.481

9.  Mutation detection of epidermal growth factor receptor and KRAS genes using the smart amplification process version 2 from formalin-fixed, paraffin-embedded lung cancer tissue.

Authors:  Yohei Miyamae; Kimihiro Shimizu; Yasumasa Mitani; Takuya Araki; Yuki Kawai; Masaru Baba; Seiichi Kakegawa; Masayuki Sugano; Kyoichi Kaira; Alexander Lezhava; Yoshihide Hayashizaki; Koujirou Yamamoto; Izumi Takeyoshi
Journal:  J Mol Diagn       Date:  2010-01-21       Impact factor: 5.568

10.  Fast simultaneous detection of K-RAS mutations in colorectal cancer.

Authors:  Ya-Sian Chang; Kun-Tu Yeh; Tien-Jye Chang; Connie Chai; Hsiu-Chin Lu; Nicholas C Hsu; Jan-Gowth Chang
Journal:  BMC Cancer       Date:  2009-06-11       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.